These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 2115694

  • 1. Interferon in the treatment of myeloproliferative diseases.
    Silver RT.
    Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Introduction and overview of interferon alfa in myeloproliferative and hemangiomatous diseases.
    Appelbaum FR.
    Semin Hematol; 1990 Jul; 27(3 Suppl 4):1-5. PubMed ID: 2197729
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H.
    Cancer; 2003 Jun 01; 97(11):2760-6. PubMed ID: 12767088
    [Abstract] [Full Text] [Related]

  • 6. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP, Sanchez SR, Ewton AA, Rice L, Perkins SL, Dunphy CH, Chang CC.
    Hum Pathol; 2008 Oct 01; 39(10):1454-8. PubMed ID: 18619646
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Chronic myeloproliferative diseases].
    Sréter L.
    Orv Hetil; 1998 Jul 26; 139(30):1779-83. PubMed ID: 9718944
    [Abstract] [Full Text] [Related]

  • 10. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
    Cortes J, Kantarjian H.
    Cancer; 2004 May 15; 100(10):2064-78. PubMed ID: 15139047
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S, Stock W, Godwin J, Fisher SG.
    Am J Hematol; 1996 May 15; 52(1):42-6. PubMed ID: 8638610
    [Abstract] [Full Text] [Related]

  • 13. [Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses].
    Linkesch W, Gisslinger H, Ludwig H, Flener R, Sinzinger H.
    Acta Med Austriaca; 1985 May 15; 12(5):123-7. PubMed ID: 3914173
    [Abstract] [Full Text] [Related]

  • 14. The management of elderly patients with myeloproliferative disorders.
    Tura S.
    Hematol Oncol; 1993 May 15; 11 Suppl 1():39-41. PubMed ID: 8486340
    [No Abstract] [Full Text] [Related]

  • 15. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y, Levine RL.
    Curr Opin Oncol; 2007 Nov 15; 19(6):628-34. PubMed ID: 17906464
    [Abstract] [Full Text] [Related]

  • 16. [New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene].
    Larsen TS, Pallisgaard N, Christensen JH, Gram-Hansen P, Kerndrup GB, Møller MB, Hasselbalch HC.
    Ugeskr Laeger; 2006 Sep 25; 168(39):3295-9. PubMed ID: 17032591
    [Abstract] [Full Text] [Related]

  • 17. [Molecular biology follow-up of interferon therapy in patients with chronic myeloid leukemia].
    Iványi JL, Marton E, Kereskai L, Kiss Z, Pajor L.
    Orv Hetil; 2000 Nov 19; 141(47):2527-33. PubMed ID: 11143285
    [Abstract] [Full Text] [Related]

  • 18. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.
    Hasselbalch HC.
    Expert Rev Hematol; 2011 Dec 19; 4(6):637-55. PubMed ID: 22077528
    [Abstract] [Full Text] [Related]

  • 19. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H, Spivak JL.
    Clin Adv Hematol Oncol; 2009 May 19; 7(5):334-42. PubMed ID: 19521323
    [Abstract] [Full Text] [Related]

  • 20. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
    Macavei I, Galatâr N.
    Morphol Embryol (Bucur); 1989 May 19; 35(2):117-27. PubMed ID: 2529429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.